Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE-PMR-2: Rituximab in Relapsing Polymyalgia Rheumatica
NCT05533164Phase 3Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Rituximab with Placebo (2 arms). Primary endpoint: Percentage of patients in glucocorticoid-free remission at 52 weeks. Started Feb 2023; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT05533164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533164.